Connect your AI

AARD AARD Other Commercial Liabilities

Other Commercial Liabilities at other companies

Relmada Therapeutics, Inc.RLMD

——

Aquestive Therapeutics, Inc.AQST

——

Other financials

Income statement

Revenue-—

Operating income-$22.5M-115%

Net income-$21.6M-132%

EPS (diluted)-$0.99-39.4%

Balance sheet

Cash & equivalents$62.4M+136%

Total debt$336.0K-53.7%

Total equity$87.0M-42.3%

Total assets$98.6M-37.2%

Cash flow

Operating cash flow-$18.9M-65.7%

CapEx--100%

Free cash flow-$16.8M-117%

Valuation

Market cap$124.35M-58.6%

Enterprise value$62.25M-77.4%

Returns & leverage

Return on equity-58.8%—

Debt / equity0×0.0×

Current ratio8.1×-17.8×

Where this comes from

Reported directly by AARD in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.

The official record: AARD’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about AARD's other commercial liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is AARD's other commercial liabilities?: AARD (AARD) reported other commercial liabilities of $6.78M in Q1 2026.
How has AARD's other commercial liabilities changed year-over-year?: AARD's other commercial liabilities increased by 123.6% year-over-year, from $3.03M to $6.78M.